Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway
The therapeutic effects and potential mechanisms of astragaloside IV on a rabbits dry eye model induced by benzalkonium chloride (BAC) was examined. In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day. The cl...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2021-04-01
|
Series: | European Journal of Histochemistry |
Subjects: | |
Online Access: | https://www.ejh.it/index.php/ejh/article/view/3198 |
id |
doaj-04a75804cad94eb0bf04328828840755 |
---|---|
record_format |
Article |
spelling |
doaj-04a75804cad94eb0bf043288288407552021-04-02T04:20:10ZengPAGEPress PublicationsEuropean Journal of Histochemistry 1121-760X2038-83062021-04-0165210.4081/ejh.2021.3198Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathwayLi Chu0Suhong Ma1Zhiwei Chen2Wenfu Cao3Chongqing Medical University, Jiulongpo District Traditional Chinese Medicine Hospital, ChongqingYunnan University of Chinese Medicine, Kunming, YunnanCollege of Traditional Chinese Medicine, Chongqing Medical University, ChongqingCollege of Traditional Chinese Medicine, Chongqing Medical University, Chongqing The therapeutic effects and potential mechanisms of astragaloside IV on a rabbits dry eye model induced by benzalkonium chloride (BAC) was examined. In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day. The clinical evaluations, such as tear break-up time (BUT) and Schirmer tear test (STT), were performed on days 0, 7, 14, 21, and 28. On day 28, the cornea and bulbar conjunctiva tissues (left eye and right eye) were collected with histology, and immunofluorescent staining conducted. The levels of MUC1 and ErbB1in the corneas were determined by real-time quantitative PCR (qRT-PCR) and the proteins levels of MUC1 and ErbB1 were detected by Western blot. It was demonstrated that both astragaloside IV (5, 10 μM) treatments resulted in an increased STT and BUT on days 7, 14, 21 and 28. Additionally, the astragaloside IV (5, 10 μM)-treated group showed increasing PAS-positive goblet cells than model group (0 μM). Moreover, the MUC1 in model group (0 μM) was decreased, while the expression of MUC1 in astragaloside IV (5, 10 μM) group was increased. Furthermore, astragaloside IV had a protective effect on BAC-induced rabbits’ dry eye and demonstrated clinical improvements, which indicated that astragaloside IV served as a potential protective agent in the clinical treatment of dry eye. https://www.ejh.it/index.php/ejh/article/view/3198AstragalosideDry eye modelMUC1ErbB1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Li Chu Suhong Ma Zhiwei Chen Wenfu Cao |
spellingShingle |
Li Chu Suhong Ma Zhiwei Chen Wenfu Cao Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway European Journal of Histochemistry Astragaloside Dry eye model MUC1 ErbB1 |
author_facet |
Li Chu Suhong Ma Zhiwei Chen Wenfu Cao |
author_sort |
Li Chu |
title |
Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway |
title_short |
Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway |
title_full |
Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway |
title_fullStr |
Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway |
title_full_unstemmed |
Astragalus Ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> MUC1-ErbB1 pathway |
title_sort |
astragalus ⅳ ameliorates the dry eye injury in rabbit model <em>via</em> muc1-erbb1 pathway |
publisher |
PAGEPress Publications |
series |
European Journal of Histochemistry |
issn |
1121-760X 2038-8306 |
publishDate |
2021-04-01 |
description |
The therapeutic effects and potential mechanisms of astragaloside IV on a rabbits dry eye model induced by benzalkonium chloride (BAC) was examined. In our study, a BAC-induced dry eye rabbit model was treated with eye drops containing astragaloside IV (5, 10 μM) or solvent four times a day. The clinical evaluations, such as tear break-up time (BUT) and Schirmer tear test (STT), were performed on days 0, 7, 14, 21, and 28. On day 28, the cornea and bulbar conjunctiva tissues (left eye and right eye) were collected with histology, and immunofluorescent staining conducted. The levels of MUC1 and ErbB1in the corneas were determined by real-time quantitative PCR (qRT-PCR) and the proteins levels of MUC1 and ErbB1 were detected by Western blot. It was demonstrated that both astragaloside IV (5, 10 μM) treatments resulted in an increased STT and BUT on days 7, 14, 21 and 28. Additionally, the astragaloside IV (5, 10 μM)-treated group showed increasing PAS-positive goblet cells than model group (0 μM). Moreover, the MUC1 in model group (0 μM) was decreased, while the expression of MUC1 in astragaloside IV (5, 10 μM) group was increased. Furthermore, astragaloside IV had a protective effect on BAC-induced rabbits’ dry eye and demonstrated clinical improvements, which indicated that astragaloside IV served as a potential protective agent in the clinical treatment of dry eye.
|
topic |
Astragaloside Dry eye model MUC1 ErbB1 |
url |
https://www.ejh.it/index.php/ejh/article/view/3198 |
work_keys_str_mv |
AT lichu astragalusivamelioratesthedryeyeinjuryinrabbitmodelemviaemmuc1erbb1pathway AT suhongma astragalusivamelioratesthedryeyeinjuryinrabbitmodelemviaemmuc1erbb1pathway AT zhiweichen astragalusivamelioratesthedryeyeinjuryinrabbitmodelemviaemmuc1erbb1pathway AT wenfucao astragalusivamelioratesthedryeyeinjuryinrabbitmodelemviaemmuc1erbb1pathway |
_version_ |
1724173326298906624 |